B. Metzler seel. Sohn & Co. Holding AG Invests $362,000 in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 18,705 shares of the biotechnology company’s stock, valued at approximately $362,000.

A number of other hedge funds also recently bought and sold shares of ARWR. Fifth Third Bancorp raised its holdings in Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares during the last quarter. Values First Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $52,000. Meeder Asset Management Inc. boosted its stake in Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 3,333 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth $96,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $18.54 on Monday. The stock has a market cap of $2.30 billion, a P/E ratio of -3.97 and a beta of 0.93. The stock’s fifty day moving average is $19.86 and its 200 day moving average is $23.21. Arrowhead Pharmaceuticals, Inc. has a one year low of $17.05 and a one year high of $39.83.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ARWR shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. Piper Sandler restated an “overweight” rating and issued a $62.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.